FDA approves liposomal vincristine (Marqibo) for rare leukemia.
D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D017322:Clinical Trials, Phase II as Topic; D017277:Drug Approval; D004337:Drug Carriers; D006801:Humans; D007390:International Agencies; D008081:Liposomes; D015337:Multicenter Studies as Topic; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D014481:United States; D014486:United States Food and Drug Administration; D014750:Vincristine / Q000008:administration & dosage*
D000972:Antineoplastic Agents, Phytogenic; D004337:Drug Carriers; D008081:Liposomes; D014750:Vincristine